Showing 1 - 20 results of 1,368 for search '(( status ((((small decrease) OR (a decrease))) OR (mean decrease)) ) OR ( _ anc decrease ))', query time: 0.57s Refine Results
  1. 1
  2. 2
  3. 3

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14

    Comparison of ANC between 2017 and 2022. by Sutapa Dey Barna (9306062)

    Published 2025
    “…</p><p>Results</p><p>In 2017--2018, 48% of women attended four or more visits, which decreased to 41% in 2022. ANC attendance for eight or more visits declined from 12% to 5%, and approximately 8% of women received no ANC in both periods. …”
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20